Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84845 | 1.00 | PRCP (0.41) | PRCPDPP7NOS2NOS3NOS1 | |
| SCHEMBL19502428 | 1.00 | PRCP (0.41) | PRCPDPP7NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL29401738 | 0.98 | PRCP (0.41) | PRCPDPP7NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL16007350 | 0.98 | PRCP (0.41) | PRCPDPP7NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL16007352 | 0.98 | PRCP (0.41) | PRCPDPP7NOS2NOS3NOS1 | |
| SCHEMBL5538288 | 0.94 | TSHR (0.40) | PRCPDPP7CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL7886550 | 0.94 | TSHR (0.40) | PRCPDPP7CYP3A4CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL7886551 | 0.93 | TSHR (0.40) | PRCPCYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL31008706 | 0.90 | TSHR (0.37) | PRCPNOS2NOS3NOS1TSHR | |
| SCHEMBL15391851 | 0.89 | PRCP (0.41) | PRCPDPP7NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105343097-A | Composition containing caffeine and application and manufacturing method of composition containing caffeine | TIANJIN JIANLAIDE TECHNOLOGY CO LTD | 2016-02-24 | — | — | CN | claimed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | UNIVERSITÄT REGENSBURG (DE) | 2022-07-12 | — | — | US | disclosed |
| US-20210069208-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2020-06-18 | — | — | US | disclosed |
| CN-108727242-A | A kind of preparation method of the trans- -4- cyclohexyl-L-PROLINE of blood-pressure drug key intermediate | 常州制药厂有限公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-108569991-A | A kind of preparation method of anti-hepatitis C virus key intermediate of medicament | 常州制药厂有限公司 | 2018-09-25 | — | — | CN | disclosed |
| US-10035791-B2 | Bicyclic compound and pharmaceutical composition thereof for treating stroke and use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2018-07-31 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0944730-A1 | METHOD FOR PRODUCTION OF D-PROLINE DERIVATIVES | LONZA A.G. (CH) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998027222-A1 | METHOD FOR PRODUCTION OF D-PROLINE DERIVATIVES | LONZA AG (CH) | 1998-06-25 | — | — | WO | disclosed |
| EP-0053017-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | PRCP 2372/4885DPP7 1588/4885NOS2 3526/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | PRCP 2778/4885DPP7 457/4885NOS2 712/4885 |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | FLT3, CSF3R, ABL1 | PRCP 1348/4885DPP7 1608/4885NOS2 447/4885 |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | FLT3, CSF3R, ABL1 | PRCP 1348/4885DPP7 1608/4885NOS2 447/4885 |
| US-20210069208-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | PRCP 2447/4885DPP7 1582/4885NOS2 3477/4885 |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | PRCP 2372/4885DPP7 1588/4885NOS2 3526/4885 |
| US-10035791-B2 | Bicyclic compound and pharmaceutical composition thereof for treating stroke and use thereof | PCSK9, NDUFC2, PCSK7 | PRCP 719/4885DPP7 1134/4885NOS2 2011/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | PRCP 2778/4885DPP7 457/4885NOS2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.